Pharmac will simplify the criteria for people accessing
COVID-19 antiviral medicines and will align the funding and
supply of these medicines with its normal
process.
Pharmac currently funds two COVID-19
antivirals for people who meet the eligibility criteria.
These antiviral medicines help to prevent people with a
COVID-19 infection from becoming severely unwell.
From
1 September 2025 the antivirals, nirmatrelvir with ritonavir
(branded as Paxlovid) and remdesivir (branded as Veklury)
will be funded for all people aged 50 years or over with an
active COVID-19 infection who are at high risk of
hospitalisation or death from COVID-19.
“This will
simplify the existing criteria and will improve access to
antivirals for people between 50 and 65 years who are high
risk and not already eligible,” says Pharmac’s Director
Pharmaceuticals, Geraldine
MacGibbon.
People who can currently access
funded COVID-19 antivirals will continue to have access to
them under the updated access
criteria.
“We’re also changing how we
manage the funding and supply of these medicines,”
MacGibbon says.
The management and supply of COVID-19
treatments was unique due to the need to respond to the
pandemic, but Pharmac is now aligning the funding and supply
of COVID-19 antivirals with its normal process.
“The
change we are making will mean pharmacies and hospitals can
order what they need from wholesalers and claim back costs
from Pharmac. This change will align the management of
COVID-19 antivirals with other funded medicines in New
Zealand,” MacGibbon says.
Advertisement – scroll to continue reading
Decision
to amend access to Covid-19 antivirals and change supply and
reimbursement
arrangements:https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-08-decision-to-amend-access-to-covid-19-antivirals-and-change-supply-and-reimbursement-arrangements
© Scoop Media



















Discussion about this post